Background. JC polyomavirus (JCPyV) is reactivated in approximately 20% of renal transplant recipients, and it may rarely cause JCPyV-associated nephropathy (JCPyVAN). Whereas progressive multifocal leukoencephalopathy of the brain is caused by rearranged neurotropic JCPyV, little is known about viral sequence variation in JCPyVAN owing to the rarity of this condition.
Human polyomaviruses (HPyVs) are widely distributed in the human population. The putative 14th HPyV was recently described [1] . After primary infection, HPyVs establish latency and remain dormant within tissues. Alterations in the immune status, specifically cell-mediated immunity, can lead to reactivation of HPyVs and result in severe clinical manifestations in immunosuppressed patients. BK polyomavirus (BKPyV) reactivation in the kidney causes BKPyV-associated nephropathy (BKPyVAN) in 5% to 8% of renal transplant recipients [2, 3] . BKPyVAN may lead to deterioration of allograft function and rarely to graft loss [3] . There is no antiviral therapy against polyomavirus-associated nephropathy (PyVAN), but the reduction of immunosuppression usually leads to a favorable outcome.
JC polyomavirus (JCPyV) is the established etiological agent of progressive multifocal leukoencephalopathy (PML), a severe demyelinating brain disease that occurs most commonly in patients with AIDS but also in transplant recipients and in patients treated with immunomodulatory drugs, such as natalizumab [4] . Although development of PyVAN due to coinfection by BKPyV and JCPyV has been reported [5] , PyVAN cases associated solely with JCPyV (JCPyV-associated nephropathy [JCPyVAN] ) are rare, and only a handful of cases, including our own, have been reported [6] [7] [8] .
JCPyV strains are classified based on the architecture of the noncoding control region (NCCR). Archetype NCCR, as in the CY strain [9] , consists of the origin of replication (117 base pairs [bp] ) and the regulatory region (267 bp), which can be further divided into sequence blocks A (36 bp), B (23 bp), C (55 bp), D (66 bp), E (18 bp), and F (69 bp) [10] . An asymptomatic primary infection, usually acquired in childhood, is caused by archetype JCPyV, and persistence is established in the kidneys, bone marrow, blood cells, including peripheral blood mononuclear cells [11] [12] [13] , and sometimes in the brain [14] . Fifty percent of adults <20 years of age are JCPyV seropositive, whereas in older age groups the seroprevalence is approximately 70% [15] . Mutated neurotropic JCPyV strains, which develop by a yet-unknown mechanism from archetype JCPyV through deletions, duplications, and rearrangements within the NCCR [9, 10, 16] , are the cause of PML. Additional point mutations in the receptor recognition region located in the VP1 capsid protein are occasionally observed [17] . Together, these alterations are thought to change JCPyV host cell tropism, a hallmark in the pathogenesis of PML [17] . Extensive studies on sequence variation in other viral genes are lacking, but recently a point mutation in the large T antigen (LTag) inhibiting the replication of neurotropic JCPyV was identified [18] . Although the majority of strains found in urine and renal tissue of renal transplant recipients to date have archetype NCCR [6, 19] , archetype-like strains with minute NCCR modifications have also been identified [12, 20] .
Using the single-molecule real-time sequencing technology by Pacific Biosciences (PacBio SMRT), amplicons several thousand base pairs in length can be sequenced in single reads [21] . Ligation of hairpin adapters to both ends of a template enables the polymerase to read individual template molecules multiple times [22] . A long polymerase read is produced, consisting of multiple subreads of the single full-length template, from which highly accurate consensus sequence can be constructed [22] .
In the present study we successfully characterized full-length JCPyV strains in urine samples from a patient with JCPyVAN and stable renal transplant recipients and evaluated the role of genetic modifications in the pathogenesis of JCPyVAN. Using PacBio SMRT, we could for the first time analyze complete JCPyV sequences originating from a single viral genome. The emphasis was on the regulatory region of NCCR and the VP1 capsid protein gene, the regions most frequently mutated in neurotropic strains and thought to affect JCPyV host cell tropism, and on the LTag gene.
METHODS

Renal Transplant Recipients
This study was approved by the institutional review board of the Helsinki and Uusimaa Hospital District. More detailed clinical information on the patients is presented in Supplementary  Table 1 and in the Supplementary Patient Data. Among patients who had received a kidney allograft between November 2007 and January 2016 in the Helsinki University Hospital and had a positive JCPyV viruria result, 20 stable renal transplant recipients had urine samples (stored at −20°C) included in the study. All renal transplant recipients except patients 16 and 17 (aged 17 and 2 years, respectively) were adults with a mean age of 49 years (range, 18-73 years) at the time of kidney transplantation. The patients were alive with a functioning kidney graft at the end of follow-up (mean follow-up, 26 months).
In addition, the cohort included a renal transplant recipient with biopsy-confirmed JCPyVAN (hereafter referred as the patient with JCPyVAN), who has been described in detail elsewhere [7] . This male patient received a cadaveric kidney allograft at the age of 15 years. At 11 months after transplantation, his kidney function deteriorated, and JCPyVAN was diagnosed. Immunosuppression was reduced owing to JCPyVAN with good response, but eventually the kidney graft was lost because of JCPyV infection and chronic antibody-mediated rejection 27 months after transplantation.
A total of 4 urine and 3 plasma samples from the patient with JCPyVAN were included in the study. These samples were taken as part of clinical follow-up during the 28 months after transplantation (Table 1) . Plasma samples 1 and 2 were taken 54 and 46 days before biopsy-confirmed interstitial nephritis, graded 1B according to the Banff criteria [23, 24] , was diagnosed. The remaining plasma sample 3 was taken 14 days after diagnosis. All urine samples (samples 4-7) were taken after diagnosis of interstitial nephritis (17, 231, 364 , and 518 days after diagnosis, respectively).
Polyomavirus Detection Using TaqMan Quantitative Polymerase Chain
Reaction
The patients were screened for BKPyV and JCPyV in urine samples by means of quantitative polymerase chain reaction (qPCR) at 3 weeks and at 3, 6, and 12 months after kidney transplantation and in the event of clinical suspicion of polyomavirus infection, unexplained graft dysfunction, or diagnosis of biopsy-proved acute rejection, as described elsewhere [25] . The plasma samples of the patient with JCPyVAN were also tested with qPCR for the presence of BKPyV and JCPyV. Total nucleic acids from fresh urine (100 µL) and plasma (200 µL) samples were extracted using a Magna Pure LC 1.0 instrument and Magna Pure LC Total Nucleic Acid Isolation kit (Roche Applied Science), eluted in 100 or 50 µL of elution buffer, respectively, and stored at −20°C until analyzed. TaqMan qPCR was performed as described elsewhere [26, 27] and amplification and detection were carried out with an ABI PRISM 7900/7500 cycler (Applied Biosystems, Life Technologies). The primer and probe sequences used are listed in Supplementary Table 2 .
Amplification of Full-Length JCPyV Genome
Total nucleic acids from 100 µL of fresh urine and 200 µL of fresh plasma were extracted as for TaqMan qPCR. Full-length JCPyV was amplified as described elsewhere [22] and the products, confirmed in 0.8% agarose gel, were provided with barcode sequences (see Supplementary Table 2 ) in a further amplification. The primers annealed to adjacent regions enabling amplification of every nucleotide in the genome (Supplementary Figure S1 ). Equal amounts of full-length barcoded PCR products were subjected to PacBio SMRT sequencing technology (Pacific Biosciences).
PacBio SMRT Sequencing and Sequence Analysis
Amplicon preparation and sequencing was done according to PacBio's protocol, which has been described elsewhere [22] . Briefly, DNA damages and ends were first repaired and then hairpin adapters were blunt ligated to the purified amplicons to generate a SMRTbell library. Exonuclease treatment was used to remove failed ligation products. The sequencing primer was annealed to the single-stranded hairpin, and DNA polymerase P6 was allowed to bind to the SMRTbell template. A PacBio RS II System with C4 chemistry was used for sequencing.
Long Amplicon Analysis tool implemented in SMRT Analysis Software (version 2.3.0) was used to find phased circular consensus sequence reads from amplicon pool. The sequences have been deposited in GenBank under accession numbers MF662180-MF662208.
Alignment of Full-Length JCPyV Sequence
The protocol described elsewhere by Seppälä et al [22] was used. Briefly, complete coding region sequences for genotypes 1A (AF015526.1), 1B (AF015527.1), 2B (AF015533.1), and 4 (AF015528.1) were retrieved from GenBank. Genotyping was based on the analysis of the coding region according to Jobes et al [28] . Numbering of nucleotides within the coding regions and amino acids presented in Results is according to genotype strains 1A, 1B, 2B, and 4. Numbering of nucleotides in the analysis of the NCCR region is according to the regulatory region of the CY strain (M35834.1) [9] .
RESULTS
In the present study, we attempted to determine JCPyV loads and characterize full-length viral strains in a total of 4 urine and 3 plasma samples from the patient with JCPyVAN. The samples were taken both before (samples 1 and 2) and after (samples 3-7) the diagnosis of biopsy-confirmed interstitial nephritis as a part of clinical follow-up within the 28 months after transplantation (Table 1) . qPCR revealed high JCPyV loads of >1.0 × 10 4 copies/mL in all urine samples. In all plasma samples the JCPyV loads remained below qPCR detection level (<400 copies/mL), although for plasma samples 2 and 3, obtained 46 days before and 14 days after diagnosis, respectively, "suggestive" JCPyV quantities of 220 and 140 copies/mL could be determined. BKPyV copy numbers remained below qPCR detection levels (<400 copies/mL for plasma and <3000 copies/mL for urine) in all samples.
Exclusively archetype JCPyV strains were identified in the urine samples from the patient with JCPyVAN ( Table 1) . The A-B-C-D-E-F architecture of the NCCR was characteristic of archetype virus, as represented by the CY strain. The NCCR of all strains was of similar length as the corresponding region of the CY strain (267 bp). The regulatory regions shared 99% sequence identity with the CY strain, and only 1 point mutation, G217A in the F block, was observed. The coding regions of viral strains in all 4 urine samples were identical and represented JCPyV genotype 4. The coding regions of all strains were 99% identical with genotype 4 strain, and they harbored point mutations scattered along the coding region. Four point mutations leading to amino acid changes beyond the receptor recognition region (V86I, A158V, V195A, and E335G) were identified in VP1. Only 1 amino acid point mutation G607E within LTag was observed. Full-length JCPyV sequences could not be obtained from any of the 3 plasma samples included (Table 1) . a BK polyomavirus copy numbers remained below quantitative polymerase chain reaction detection levels in all samples (<400 and <3000 copies/mL for plasma and urine samples, respectively). Full-length JCPyV strains were also characterized from urine samples of 20 renal transplant recipients with stable graft function (Table 2) . In all samples from adult patients, high JCPyV DNA loads in urine (range, 1.0 × 10 4 to 1.0 × 10 8 copies/mL) were detected. Similarly, high JCPyV quantities were also observed in urine samples from adolescent patients 16 and 17 (1.64 × 10 6 and 5.98 × 10 7 copies/mL, respectively). BKPyV DNA remained below the qPCR detection level in all samples (Table 2) . Interestingly, a JCPyV strain with modified NCCR architecture could be identified in a stable renal transplant recipient with minor graft dysfunction (patient 11). The NCCR was 253 bp long owing to 8-bp and 6-bp deletions at the 3´ end of the archetypal B block (nucleotides 52…59) and the 5´end of the archetypal C block (nucleotides 60…65). The NCCR architecture of this strain was thus A-(B)-(C)-D-E-F (where parentheses indicate a truncated block). Two point mutations (G217A, T229C) in the F block were also distinguished. Amino acid sequence analysis of VP1 and LTag revealed 3 amino acid changes beyond the receptor recognition region of VP1 (G8A, L158V, K345R) and 1 point mutation (S653F) within LTag. Among the other 19 stable renal transplant recipients, the length and architecture of the regulatory regions of NCCR were similar to those of the CY strain and shared 99% sequence identity with CY. All strains had a point mutation G217A in the F block, among some additional scattered point mutations ( Table 2) .
Analysis of the coding region among stable renal transplant recipients revealed JCPyV genotype 1A in 7 patients and genotype 1B in 10. Two patients had genotype 4, and 1 had genotype 2B ( Table 2) . None of the patients had multiple genotypes. The patient strains shared 99% homology with respective genotype strains, and all patient strains had nucleotide point mutations scattered along the coding region. A more detailed amino acid sequence analysis of VP1 and LTag was performed (Table 2) . Strains belonging to the genotypes 1A and 1B had some point mutations within the VP1 receptor recognition loops BC (K75R, V64I, S222N and D52N) or DE (T128S). Occasional point mutations in the origin binding (L160F), zinc finger (T357S) or helicase (K507R) domains of LTag were detected. Both genotype 4-positive patients had identical point mutations within VP1 (V86I, A158V, V195A, E335G) and LTag (G607E) located outside the receptor recognition region of VP1 and the functional domains of LTag, respectively. The genotype 2B strain found in 1 patient had 1 origin binding domain mutation within LTag (A161S) but no VP1 mutations.
Finally, 2 individual JCPyV strains representing the same genotype were found in urine samples from 5 stable renal transplant recipients (patients 9, 13, 15, 18, and 19). The 2 strains of a single patient were always 99% identical. The strain-specific differences were observed within the coding region, except in patient 18, in whom the only difference between the 2 strains was identified at nucleotide 95 within the NCCR (Table 2) . Interestingly, strains retrieved from patient 19 differed within the VP1 gene. The strain 19.2 differed only at 1 nucleotide (1346) from strain 19.1, which led to an additional VP1 point mutation (D52N) compared with the genotype strain. No differences were observed between the LTag amino acid sequences of these 2 strains. VP1 and LTag from the 2 strains in patients 9, 13, and 15 differed only in silent nucleotide point mutations not leading to amino acid changes. Strain 9.2 of patient 9 had a 12-bp deletion in the agnoprotein gene (127…139) not present in strain 9.1 from the same patient.
DISCUSSION
This is the first study, to our knowledge, in which full-length archetype JCPyV strains have been characterized from the urine of renal transplant recipients with biopsy-confirmed JCPyVAN or stable graft function. Involvement of rearranged JCPyV strains in the pathogenesis of PML, a fatal brain disease, has been established [16] . Whether rearrangements take place in the pathogenesis of JCPyVAN, or whether archetype strains have a pathogenic role, is less well understood.
Although asymptomatic high-level JCPyV viruria occurs in 16.8%-27.2% and viremia in 14.2% of renal transplant recipients after kidney transplantation [29, 30] , JCPyVAN is an extremely rare disease [6, 8] . Except for JCPyV replication in the kidneys, the exact predisposing factors are unknown [6] . In our study, full-length JCPyV strains present in the urine of a patient with JCPyVAN described earlier [7] were characterized. Solely archetype NCCR architecture was detected, consistent with previously reported cases [29, 31] . We could not obtain full-length JCPyV sequence from any of the plasma samples included, which may be explained by the very low JCPyV loads in the plasma of this patient [7] and other reported patients with JCPyVAN [6, 29] . Unspecific amplification of the abundant human DNA in plasma may further interfere with specific amplification of very scarce viral DNA.
Our results indicate that JCPyVAN was due to efficiently contained replication of archetype JCPyV in the kidneys without major viral spread via a hematogenous route. Intriguingly, the patient was retrospectively shown to be JCPyV seronegative before transplantation; JCPyVAN developed because of primary JCPyV infection on transplantation [7] . In the case of BKPyV, donor BKPyV seroreactivity has been proposed as a risk factor for the development of recipient BKPyVAN [32] . JCPyVAN may thus be associated with the primary JCPyV infection in this pediatric renal transplant recipient. Whether primary JCPyV infection experienced on transplantation could increase the overall risk of JCPyVAN needs to be further investigated. Considering the more common BKPyV etiology, samples from this particular patient were previously tested for BKPyV DNA or antibodies, but with negative results [7] . We cannot completely rule out the possibility that very low levels of BKPyV may have remained undetected by our methods.
In the present study, archetype JCPyV strains were also found in the urine of all except 1 stable renal transplant recipient. These patients did not experience any graft dysfunction during sampling. Our results further support the current understanding that replication of archetype JCPyV strains in the kidneys does not usually involve symptomatic clinical manifestations [9, 33] . All archetype strains harbored a previously identified point mutation G217A in the regulatory region of NCCR, which is absent in the CY strain [34] but common in European strains belonging to genotypes 1 and 4 [35, 36] . In agreement with previous studies [9, 33] , no rearranged JCPyV strains were found in urine samples from immunosuppressed patients. Our results support the hypothesis of archetype JCPyV circulating in the population [9, 15, 35, 36] . However, this needs to be established by comprehensive virus isolation and characterization from clinical samples.
JCPyV NCCR contains binding sites for a number of cellular transcription factors needed for viral replication in the host cell. For example, the enhanced replication of neurotropic JCPyV strains in glial cells of the brain is thought to be due to changes in the binding sites for transcription factors such as Spi-B [37] . In the current study, a JCPyV strain with slightly rearranged, archetype-like NCCR lacking 1 binding site for NF-1 transcription factor was identified in a patient who had experienced minor graft dysfunction. NF-1 is an important regulator of JCPyV replication in JCPyV-permissive cells [38] . Similar deletion has been found in urine JCPyV strains of renal transplant recipients [39] . Emergence of strains with archetype-like NCCR in kidneys is not uncommon, and they can be detected in urine samples from both immunocompetent and immunosuppressed individuals, including renal transplant recipients and patients with autoimmune diseases [20, [39] [40] [41] . It has also been proposed that immunosuppression may increase the emergence of rearranged strains in renal transplant recipients [12] . Our findings are consistent with the presumption that infection of kidney cells by JCPyV strains with NCCR regions identical or similar to those of the archetype strains is not associated with severe kidney problems [30] .
Point mutations in the receptor recognition region located in VP1 are considered to change the host cell tropism of JCPyV toward brain glial cells [17] . The VP1 amino acids 48-81, 119-138, and 261-269 of the neurotropic prototype strain Mad-1 form receptor recognition loops BC, DE and HI, respectively [42] . In the present study, viral strains were identified with VP1 point mutations affecting the outer loops of BC (D52N, V64I, K75R) and DE loops (T128S). However, no previously recognized neurotropic VP1 mutations affecting JCPyV cell tropism [17] were observed. All VP1 mutations except the point mutation D52N have been previously detected in urine JCPyV strains of immunocompetent individuals [41, 43, 44] . Furthermore, the point mutations G8A, L158V and K345R have been identified in neurotropic strains of patients with PML or JCPyV granule cell neuronopathy [22, 45] . VP1 is the major capsid protein and serves as an important antigen for cell-mediated immunity; thus, rather than affecting the host cell tropism of JCPyV, VP1 point mutations in archetype strains might enhance viral immune evasion. However, none of the identified VP1 point mutations affected the established epitopes recognized by cytotoxic T cells [46, 47] .
In addition, some point mutations within LTag were identified in all JCPyV strains. None of the strains harbored the LTag point mutation V392G recently reported to repress JCPyV replication [18] . The role of LTag mutations in JCPyV replication has not yet been thoroughly explored.
Finally, JCPyV strains representing slightly altered quasispecies were identified in urine samples from 5 stable renal transplant recipients. Previously, renal transplant recipients have been shown to secrete >1 JCPyV strain, but unlike in our study, these strains represented different genotypes [48] . The very sensitive sequencing technique used in the current is expected to improve the ability to distinguish several strains of the same genotype; the differences between viral strains from the same individual were scattered along the coding region. JCPyV strains from individual urine samples have been shown before to contain distinct NCCRs [41] . The changes we observed were mostly point mutations, but the 2 strains from 1 patient differed by a larger, 12-bp deletion within the agnoprotein gene. A similar deletion has been shown to disable JCPyV from causing persistent infection in the kidneys [49] , although in our case the overall JCPyV replication was efficient. One might assume that the presence of JCPyV quasispecies in the kidneys would be advantageous for viral fitness, but no differences were seen in clinical status between stable renal transplant recipients with 1 or 2 viral strains. We are not able to establish whether the JCPyV quasispecies emerged in the organism of the recipient, or whether 1 strain originates from the donor, similar to what has been reported for BKPyV [50] .
To our knowledge, this is the first attempt to amplify and characterize full-length JCPyV strains present in urine and plasma of renal transplant recipients. By using single-molecule real-time sequencing, we were able to identify changes in the NCCR, VP1 and LTag regions within a single viral strain. Whereas JCPyV sequence variation plays a crucial role in the pathogenesis of PML, this study suggests a minor role for viral genome modifications in the pathogenesis of JCPyVAN.
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